Compare ORIO & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORIO | TXMD |
|---|---|---|
| Founded | N/A | 2008 |
| Country | Canada | United States |
| Employees | 188 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3M | 24.3M |
| IPO Year | N/A | 2012 |
| Metric | ORIO | TXMD |
|---|---|---|
| Price | $0.98 | $2.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 39.4K | 20.2K |
| Earning Date | 03-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | $74.52 | N/A |
| Revenue Next Year | $5.07 | N/A |
| P/E Ratio | ★ $4.93 | $201.50 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.90 | $0.98 |
| 52 Week High | $1.40 | $2.95 |
| Indicator | ORIO | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 37.85 | 46.25 |
| Support Level | N/A | $1.93 |
| Resistance Level | $1.11 | $2.05 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 8.33 | 37.16 |
Orion Digital Corp is a financial technology company operating digital platforms across wealth and payments, supported by a consumer lending business in Canada. The Company's Wealth platform, Intelligent Investing, provides long-term investment solutions to the Canadian market. It also operates a consumer lending business in Canada. Its Payments business is conducted through its wholly owned subsidiary, which provides issuer processing, program management, and regulated payment orchestration services across Europe. The Company operates in Canada and Europe, with Canada generating the majority of its revenue.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.